Efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma
Li, R-cheng.; Yang, J-ye.; Gong, J.; Li, Y-ping.; Huang, Z-neng.; Fang, K-xiong.; Xu, Z-yi.; Liu, C-bai.; Zhao, K.; Zhuang, H.
Zhonghua Liu Xing Bing Xue Za Zhi 25(5): 385-387
2004
ISSN/ISBN: 0254-6450 PMID: 15231157 Document Number: 582937
To evaluate the efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma. Birth cohort study, cross-sectional seroepidemiological survey, and surveillance of hepatitis B (HBV) and hepatocellular carcinoma were used to evaluate the efficacy of hepatitis B vaccination. During the 14 years after hepatitis B vaccination, the HBsAg positive rates were found to be 0.7% - 2.9%, with an average of 1.5%, and the protective rates were 83.5% - 96.6%. Hepatitis B virus infection rates of children immunized with hepatitis B vaccine were 1.1% - 5.1%, with an average of 2.2% and the protective rates of 93.5% - 98.4%. 15 years after hepatitis B vaccination, the incidence of hepatitis B dropped from 3.27/10 000 to 0.17/10 000, a 94.8% decrease, in the group of 0 - 19 year-olds. The universal infant hepatitis B vaccination has proved to be effective in reducing the incidence rate of acute hepatitis B as well as the mortality of hepatocellular carcinoma.